皓元医药: 民生证券股份有限公司关于上海皓元医药股份有限公司2025年半年度持续督导跟踪报告

| | | | | CDMO | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | -1,043.09 | | 7,709.98 | % -113.53 | | | | | | | | | | % | | | | | | | | | | | | % | | | | | | % | | 5.15 | 2.74 | | | % | | | | | | | | | | | | | | % | | 8.92 | 10.63 | | | / | / | + | | | | | | | | | | | | CDMO | | | | | | | | GMP | IND | NDA&ANDA | MAH | | | | | XDC | | PROTAC | | | | | | | | | | | | CRO | | | [2024]1289 | | | | | [2024]200Z0069 | | | | | | | | CDMO | | | | | | | | | / / Gu < > ...